US · ATR · MEDICAL - INSTRUMENTS & SUPPLIES
AptarGroup, Inc. (ATR) intrinsic value and stock valuation
$140.08as of 2026-11-21 · Mkt cap 8.64B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
AptarGroup, Inc. DCF and intrinsic value
InvestorsCraft values ATR with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ATR’s statements →
AptarGroup, Inc. Graham Number
Graham Number: $74.47d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Globus Medical, Inc. (GMED) $66.89
- Henry Schein, Inc. (HSIC) $83.52
- Molina Healthcare, Inc. (MOH) $198.39
- Halozyme Therapeutics, Inc. (HALO) $91.35
- Avantor, Inc. (AVTR) $14.84
- Repligen Corporation (RGEN) $163.81
- Grifols, S.A. (GRFS) $8.15
- Teleflex Incorporated (TFX) $161.58
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.78B | $3.58B | $3.49B | $3.32B | $3.23B |
| Operating income | $512.3M | $496.5M | $404M | $379.3M | $347.4M |
| Net income | $392.8M | $374.5M | $284.5M | $239.3M | $244.1M |
| EPSd | $5.89M | $5.53M | $4.25M | $3.59M | $3.61M |
| Operating cash flow | $570M | $643.4M | $575.2M | $478.6M | $363.4M |
| Capital expenditure | -$-270.42M | -$-294.19M | -$-318.4M | -$-315.62M | -$-307.94M |
| Free cash flow | $299.6M | $349.2M | $256.8M | $163M | $55.5M |
| Total assets | $5.25B | $4.43B | $4.45B | $4.2B | $4.14B |
| Total debt | $1.53B | $1.08B | $1.18B | $1.22B | $1.24B |
| Net debt | $1.13B | $852.2M | $961M | $1.08B | $1.12B |
| Total equity | $2.71B | $2.49B | $2.32B | $2.07B | $1.98B |
| Cash and short-term investments | $409.5M | $226.2M | $223.6M | $141.7M | $123.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.78B | $3.58B | $3.49B | $3.32B | $3.23B |
| Cost of revenue | $2.66B | $2.23B | $2.22B | $2.16B | $2.07B |
| Gross profit | $1.12B | $1.36B | $1.26B | $1.16B | $1.16B |
| Research and development expenses | $105.1M | $0.00 | $0.00 | $0.00 | $99.8M |
| Selling, general and administrative expenses | $499.9M | $582.2M | $565.8M | $544.3M | $551.2M |
| Other expenses | $0.00 | $276.8M | $293.6M | $240.3M | $158.3M |
| Operating expenses | $605M | $859M | $859.4M | $784.6M | $809.3M |
| Cost and expenses | $3.26B | $3.09B | $3.08B | $2.94B | $2.88B |
| Interest income | $11.7M | $12.1M | $4.37M | $2.7M | $3.67M |
| Interest expense | $52.7M | $43.9M | $40.4M | $40.8M | $30.3M |
| Depreciation and amortization | $287.4M | $263.8M | $248.6M | $233.7M | $234.9M |
| Ebitda | $831.5M | $777.5M | $663.8M | $609.4M | $586.8M |
| Operating income | $512.3M | $496.5M | $404M | $379.3M | $347.4M |
| Total other income/expenses, net | -$-20.96M | -$-26.73M | -$-29.19M | -$-44.57M | -$-25.69M |
| Income before tax | $491.4M | $469.8M | $374.8M | $334.7M | $321.7M |
| Income tax expense | $98.9M | $95.6M | $90.7M | $95.2M | $78M |
| Net income | $392.8M | $374.5M | $284.5M | $239.3M | $244.1M |
| Weighted average shares outstanding | $65.7M | $66.3M | $65.6M | $65.4M | $65.7M |
| Weighted average diluted shares outstanding | $66.7M | $67.7M | $66.9M | $66.7M | $67.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $409.5M | $226.2M | $223.6M | $141.7M | $123.7M |
| Net receivables | $803.8M | $658.1M | $677.8M | $677M | $671.4M |
| Inventory | $537.9M | $461.8M | $513.1M | $486.8M | $441.5M |
| Total current assets | $1.89B | $1.48B | $1.55B | $1.43B | $1.36B |
| Property, plant and equipment, net | $1.74B | $1.51B | $1.54B | $1.4B | $1.34B |
| Goodwill and intangible assets | $1.33B | $1.19B | $1.25B | $1.26B | $1.34B |
| Long-term investments | $131M | $146.3M | $49.2M | $52.3M | $59.5M |
| Total non-current assets | $3.36B | $2.95B | $2.9B | $2.77B | $2.78B |
| Total assets | $5.25B | $4.43B | $4.45B | $4.2B | $4.14B |
| Accounts payable | $340.6M | $296M | $328.6M | $320.3M | $285.3M |
| Short-term debt | $343.5M | $338.3M | $458.2M | $126M | $289.6M |
| Deferred revenue | $74.8M | $64.4M | $60.5M | $80.2M | $87M |
| Total current liabilities | $1.17B | $1.07B | $1.25B | $917.2M | $982.5M |
| Long-term debt | $1.19B | $737.8M | $726.5M | $1.1B | $955M |
| Deferred revenue, non-current | $0.00 | $0.00 | $37.8M | $25.4M | $21.9M |
| Total non-current liabilities | $1.37B | $878.1M | $879.3M | $1.22B | $1.17B |
| Capital lease obligations | $47.9M | $49.7M | $45.3M | $46.2M | $51.8M |
| Total liabilities | $2.54B | $1.95B | $2.13B | $2.14B | $2.16B |
| Common stock | $730K | $720K | $720K | $710K | $700K |
| Retained earnings | $2.64B | $2.37B | $2.11B | $1.93B | $1.79B |
| Accumulated other comprehensive income (loss) | -$-186.38M | -$-429.48M | -$-308.73M | -$-341.37M | -$-316.04M |
| Total equity | $2.71B | $2.49B | $2.32B | $2.07B | $1.98B |
| Total investments | $138.1M | $148.6M | $49.2M | $52.3M | $60.2M |
| Total debt | $1.53B | $1.08B | $1.18B | $1.22B | $1.24B |
| Net debt | $1.13B | $852.2M | $961M | $1.08B | $1.12B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $392.8M | $374.2M | $284.2M | $239.6M | $243.6M |
| Depreciation and amortization | $287.4M | $263.8M | $248.6M | $233.7M | $234.9M |
| Stock-based compensation | $0.00 | $47.7M | $41.3M | $40.9M | $38.9M |
| Change in working capital | -$-125.45M | -$-32.26M | $5.75M | -$-45M | -$-169.69M |
| Accounts receivable | -$-73.89M | -$-18.08M | $15.4M | -$-27.94M | -$-123.25M |
| Inventory | -$-10.65M | $21.9M | -$-10.64M | -$-60.35M | -$-79.96M |
| Accounts payable | -$-18.27M | -$-23.7M | $14.6M | $55.1M | $52.3M |
| Net cash provided by operating activities | $570M | $643.4M | $575.2M | $478.6M | $363.4M |
| Investments in property, plant and equipment | -$-275.44M | -$-294.19M | -$-318.4M | -$-315.62M | -$-307.94M |
| Acquisitions, net | -$-55.87M | $0.00 | -$-16.57M | -$-4.1M | -$-148.42M |
| Net cash used for investing activities | -$-330.64M | -$-396.72M | -$-324.46M | -$-295.64M | -$-457.24M |
| Common stock issued | $18.9M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-365M | -$-68.64M | -$-47.55M | -$-92.13M | -$-78.15M |
| Dividends paid | -$-120.78M | -$-114.06M | -$-103.68M | -$-99.46M | -$-98.51M |
| Net cash used for financing activities | -$-78.26M | -$-225.34M | -$-171.55M | -$-162.1M | -$-81.52M |
| Net change in cash | $178.1M | $200K | $81.4M | $19.8M | -$-182.04M |
| Cash at end of period | $402.4M | $224.3M | $224.1M | $142.7M | $122.9M |
| Operating cash flow | $570M | $643.4M | $575.2M | $478.6M | $363.4M |
| Capital expenditure | -$-270.42M | -$-294.19M | -$-318.4M | -$-315.62M | -$-307.94M |
| Free cash flow | $299.6M | $349.2M | $256.8M | $163M | $55.5M |
Line items
Line items
Line items
About AptarGroup, Inc.
AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.
- CEO
- Stephan Tanda
- Employees
- 14K
- Beta
- 0.39
Included in
Explore
Frequently asked questions
What is the intrinsic value of AptarGroup, Inc. (ATR)?
AptarGroup, Inc. (ATR) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ATR undervalued?
ATR trades at a price of $140.08 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.